Beleave Inc. (“Beleave”) (CSE:BE) (OTCQX:BLEVF) strongly supports The City of Hamilton council’s decision to turn down the motion for any new restrictions pertaining to the land use planning framework for the cannabis industry.  The company continues to move forward with its facility expansion in the community of Flamborough, in the city of Hamilton, Ontario, for which it has engaged Havecon North America Inc., subsidiary of Havecon Kassenbouw, a leading Dutch-based greenhouse builder.

“Since locating in Flamborough we have been dedicated to working with the City of Hamilton to develop a framework that has allowed for a mutually beneficial relationship,” commented Beleave COO Bill Panagiotakopoulos, “We will continue to offer our full support to ensure we are all putting our best foot forward together.”


A motion proposing certain land-use planning restrictions aimed at the cannabis sector was tabled on October 11th, 2017.  Following consultations with local Licensed Producers and other stakeholders, the motion was withdrawn by a vote of twelve representatives to three.  The decision underpins the company’s belief that Hamilton is a strong and vibrant economy to base its operations.

The city, like many across the country, will continue to review the framework for the cannabis industry which is natural given the infancy of the sector as a whole.

About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.

For more information contact:
Sebastian de Kloet
Phone: 1 (905) 979 – 5173
Email: Sebastian@beleave.com
Click here to connect with Beleave Inc. (CSE:BE,OTCQX:BLEVF) for an Investor Presentation

Source: globenewswire.ca

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less